^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Secondary therapy:
BRAF inhibitor
Source:
Title:
Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
Excerpt:
...4.Has been untreated for advanced disease except as follows: a.BRAF V600 mutation-positive melanoma may have received SOC targeted therapy as 1L therapy for advanced disease (eg, BRAF/MEK inhibitor, alone or in combination). ...
Trial ID:
Source:
Title:
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
Excerpt:
...Consent to the evaluation of the PD-L1 status and BRAF V600 mutation status ; 7....
Trial ID:
More C2 evidence
Source:
Title:
A single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in adults with unresectable or metastatic melanoma Studio a braccio singolo volto a valutare l’efficacia e la sicurezza di EVX-01 in combinazione con pembrolizumab in adulti affetti da melanoma non resecabile o metastatico
Excerpt:
...Patientswith BRAF V600E mutant melanoma may have received prior BRAFinhibitor therapy as first-line systemic therapy and be eligible for this trial assecond line treatment. ...
Trial ID:
Source:
Title:
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Excerpt:
...BRAF V600 mutation patients must have progressed on, or are intolerant to, BRAF +/- MEK inhibitor therapy....
Trial ID:
Source:
Title:
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Excerpt:
...Irrespective of PD-L1 result and BRAF V600 mutation 4....
Trial ID:
Source:
Title:
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
Excerpt:
...BRAF V600 mutant melanoma may have received standard of care targeted therapy (e.g....
Trial ID:
Source:
Title:
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Excerpt:
...- Unresectable or metastatic disease progression following a BRAF inhibitor if BRAF V600 positive -...
Trial ID:
Source:
Title:
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
Excerpt:
...Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of metastatic melanoma with BRAF V600E/K mutation will be enrolled in this study....
Trial ID:
Source:
Title:
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Excerpt:
...- Documentation of V600E-activating BRAF mutation status....
Trial ID:
Source:
Title:
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Excerpt:
...If the melanoma expresses a BRAF mutation of V600E, V600K, or V600R patient must have received and progressed through a BRAF inhibitor or have failed that therapy due to toxicity....
Trial ID:
Source:
Title:
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
Excerpt:
...- Histologically/cytologically confirmed stage IV BRAF V600E or K metastatic melanoma...
Trial ID:
Source:
Title:
Phase 3 Study of Epacadostat and Pembrolizumab in Melanoma
Excerpt:
...BRAF V600 mutant melanoma may have received standard of care targeted therapy (e.g. BRAF/MEK inhibitor, alone or in combination) and be eligible for this study Note: Targeted therapy is not required for eligibility. ...
Trial ID:
Less C2 evidence
Source:
Title:
First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma
Published date:
09/03/2022
Excerpt:
To investigate the outcomes associated with first-line pembrolizumab or dabrafenib/trametinib treatment for advanced melanoma with activating BRAF V600 mutation….Pembrolizumab may be recommended over BRAF/mitogen-activated protein kinase kinase inhibitors as the first-line treatment in patients with advanced BRAF V600-mutant melanoma.
DOI:
10.1016/j.jaad.2022.07.057
